Status:
UNKNOWN
Assistance Program for Outpatients Following an Allogeneic Hematopoietic Stem-cell Transplant
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Hematologic Neoplasms
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
After the initial monitoring period during hospitalization and isolation, patients with recent transplants are regularly monitored in monthly consultations but are still fragile, immunosuppressed and ...
Eligibility Criteria
Inclusion
- Adult patients over 18 years of age
- Having received an allogeneic hematopoietic stem-cell transplant
- In full remission
- Outpatients
- Having given their informed consent for the participation in the outpatient assistance program with a navigation nurse (AMA-ALLO) at the first post-transplant consultation (starting on Day 100 +/- 10 days post-transplant i.e., when the patient passes the initial post-transplant monitoring period in hospitalization (conventional or by day) to the monitoring period in monthly medical consultations) and continuing for 12 months
- Affiliated with the social security system
Exclusion
- Transplant patients not having given their informed consent for inclusion in AMA-ALLO
- Hospitalized or non-outpatient transplant patients
- Post-transplant patients in cytological relapse
- Patients under a legal regime of adult protection (guardianship, curatorship, etc.)
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04323605
Start Date
January 1 2021
End Date
February 1 2022
Last Update
December 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toulouse University Hospital
Toulouse, France